This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.
Express Scripts (ESRX) Q4 Earnings Top, Long-Term View Solid
by Zacks Equity Research
Express Scripts' (ESRX) fourth-quarter 2017 results benefit from rise in patient claims and strong customer retention.
MedTech's Long-Term Prospects Outweigh Near-Term Risks
by Mark Vickery
A growing prevalence of minimally invasive surgeries, rising demand for liquid biopsy tests, use of IT for ensuring quick and improved patient care and the shift of the payment system to a value-based model are among the updates.
STERIS Focuses on Expanding Core Business, Competition Rife
by Zacks Equity Research
STERIS (STE) pursues six acquisitions in the first nine months of fiscal 2018.
Here's Why You Should Invest in LabCorp (LH) Stock Right Now
by Zacks Equity Research
Strong guidance and Covance Drug Development's sturdy growth raise investors optimism on LabCorp (LH).
Henry Schein (HSIC) Q4 Earnings in Line, 2018 View Upbeat
by Zacks Equity Research
Henry Schein's (HSIC) strong share gains in the North American and overseas markets along with solid revenues raise optimism.
AmerisourceBergen (ABC) Jumps: Stock Rises 9.3%
by Zacks Equity Research
AmerisourceBergen (ABC) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
GNC Holdings to Boost International Business With New Deals
by Zacks Equity Research
GNC Holdings (GNC) adopts initiatives to boost contributions from international business with strong focus on China.
GNC Holdings (GNC) Tops Q4 Earnings, Lags Revenue Estimates
by Zacks Equity Research
Despite sluggish performance by manufacturing/wholesale segments, GNC Holdings (GNC) witnesses revenue growth in Q4.
CVS Health (CVS) Q4 Earnings Beat Estimates, '18 View Upbeat
by Zacks Equity Research
A strong Pharmacy Services segment, benefiting from the upside in the specialty services Drives CVS Health's (CVS) topline in Q4.
Cardinal Health (CAH) Beats on Q2 Earnings, Raises '18 View
by Zacks Equity Research
Solid performance at the Medical Segment drove Cardinal Health (CAH) in Q2.
STERIS (STE) Q3 Earnings Beat & Revenues Miss, Margins Up
by Zacks Equity Research
STERIS (STE) witnesses year-over-year rise in Q3 revenues on favorable underlying market trends along with new product and service offerings.
CAH vs. HOLX: Which Will Fare Better This Earnings Season?
by Zacks Equity Research
Here we look at the major factors that are likely to influence the earnings results of a few MedTech bigwigs within the broader Medical universe.
Becton (BDX) Beats on Q1 Earnings and Revenues Estimates
by Zacks Equity Research
Becton, Dickinson and Company (BDX) delivers strong performance in Q1 on the back strong segmental performance.
Medical Product Stocks' Earnings on Feb 6: BDX, LH & More
by Zacks Equity Research
Here we take a look at the major factors that are likely to influence the earnings results of a few MedTech bigwigs.
Should You Buy Becton, Dickinson (BDX) Ahead of Earnings?
by Zacks Equity Research
Becton, Dickinson (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Quality Systems (QSII) Q3 Earnings in Line, Revenues Beat
by Zacks Equity Research
Quality Systems (QSII) benefits from solid bookings and acquisitions in Q3.
What's in Store for Becton, Dickinson (BDX) in Q1 Earnings?
by Zacks Equity Research
Despite solid prospects in the emerging markets, Becton, Dickinson (BDX) is likely to witness sluggishness in BD Medical and BD Life Sciences in Q1.
Becton, Dickinson (BDX), Bard Receive Regulatory Nod in China
by Zacks Equity Research
Favorable tidings on the regulatory front have boosted Becton, Dickinson and Company (BDX) lately. After the closure of the deal, the company will establish a new business segment.
Becton, Dickinson (BDX) a Step Closer to Bard Acquisition
by Zacks Equity Research
Becton, Dickinson and Company (BDX) gets FTC's nod for the acquisition of C. R. Bard.
Merit Medical Deserves a Place in Your Portfolio: Here's Why
by Zacks Equity Research
A slew of bolt-on acquisitions leverages Merit Medical (MMSI) to drive inorganic growth.
The Zacks Analyst Blog Highlights: Morris, EOG Resources, Becton, Dickinson, Sirius XM and ABB
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Morris, EOG Resources, Becton, Dickinson, Sirius XM and ABB
Becton, Dickinson Banks on Bard Buyout, Medical Unit Weak
by Zacks Equity Research
Becton, Dickinson (BDX) is steadily progressing with the acquisition of C. R. Bard. However, sluggishness in the Medical Segment is a headwind.
Becton, Dickinson Focuses on Medication Management, Stock Up
by Zacks Equity Research
Management at Becton, Dickinson and Company (BDX) has been focusing on strengthening its portfolio for long.
Becton Dickinson (BDX) in Focus: Stock Moves 7.7% Higher
by Zacks Equity Research
Becton Dickinson (BDX) saw its shares rise nearly 8% on the day after the company posted better-than-expected third-quarter results.
Becton (BDX) Tops Q4 Earnings and Revenues Estimates
by Zacks Equity Research
Becton, Dickinson???s adjusted earnings of $2.40 per share beat the Zacks Consensus Estimate by 2 cents and increased from $2.12 posted in the year-ago quarter.